Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE